Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2BTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3MPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PPARGSLC6A2SLC6A3SLC6A4SMOTYK2pol
The experimentally established mechanism targets of Irsogladine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.73 |
| ▸ | JAK2 known ✓ | O60674 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.73 |
| ▸ | CDK9 | P50750 | 4/20 | 0.43 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.42 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CASP3 | P42574 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Irsogladine SCHEMBL3308315 | 1.00 | HTR2B (0.73) | HTR2BPDE4DCDK9SCN10AAGPAT2 | |
| Irsogladine SCHEMBL29518346 | 1.00 | HTR2B (0.73) | HTR2BPDE4DCDK9SCN10AAGPAT2 | |
| Irsogladine SCHEMBL8447523 | 1.00 | HTR2B (0.73) | HTR2BPDE4DCDK9SCN10AAGPAT2 | |
| Irsogladine SCHEMBL28287178 | 0.99 | HTR2B (0.71) | HTR2BPDE4DCDK9SCN10AAGPAT2 | |
| Irsogladine SCHEMBL29517870 | 0.86 | HTR2B (1.00) | HTR2BPDE4DCDK9AGPAT2NPC1 | |
| Irsogladine SCHEMBL62215 | 0.86 | HTR2B (1.00) | HTR2BPDE4DCDK9AGPAT2NPC1 | |
| Maleic Acid SCHEMBL8412361 | 0.79 | HTR2B (0.46) | HTR2BPDE4DCDK9 | |
| Fumaric Acid SCHEMBL8412364 | 0.79 | HTR2B (0.46) | HTR2BPDE4DCDK9 | |
| Irsogladine SCHEMBL28157836 | 0.78 | HTR2B (0.45) | HTR2BPDE4DCDK9NPC1RAB9A | |
| SCHEMBL8412370 | 0.78 | HTR2B (0.83) | HTR2BPDE4DCDK9SCN10AAGPAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 605 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12478627-B2 | Irsogladine for the treatment of eosinophilic gastrointestinal diseases | EPITHELION SCIENCE BIOTECH, S.L. (ES) | 2025-11-25 | — | — | US | claimed |
| WO-2024237610-A1 | COLONIC PURGATIVE TABLET AND COLONIC PURGATIVE COMPRISING SAME | 주식회사 한국팜비오 | 2024-11-21 | — | — | WO | claimed |
| EP-3980020-B1 | IRSOGLADINE FOR THE TREATMENT OF EOSINOPHILIC GASTROINTESTINAL DISEASES | EPITHELION SCIENCE BIOTECH S L (ES) | 2023-08-23 | — | — | EP | claimed |
| US-20220226333-A1 | IRSOGLADINE FOR THE TREATMENT OF EOSINOPHILIC GASTROINTESTINAL DISEASES | EPITHELION SCIENCE BIOTECH, S.L. (ES) | 2022-07-21 | — | — | US | claimed |
| CN-114478414-A | Novel synthesis process method of gastric mucosa protective medicine | 苏州虞美景盛新药开发有限公司 | 2022-05-13 | — | — | CN | claimed |
| EP-3980020-A1 | IRSOGLADINE FOR THE TREATMENT OF EOSINOPHILIC GASTROINTESTINAL DISEASES | Epithelion Science Biotech, S.L. (ES) | 2022-04-13 | — | — | EP | claimed |
| WO-2020245382-A1 | IRSOGLADINE FOR THE TREATMENT OF EOSINOPHILIC GASTROINTESTINAL DISEASES | EPITHELION SCIENCE BIOTECH, S.L. (ES) | 2020-12-10 | — | — | WO | claimed |
| US-10639308-B2 | sGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2020-05-05 | — | — | US | claimed |
| CN-106187928-B | A kind of preparation method of irsogladine maleate | 安徽省逸欣铭医药科技有限公司 | 2019-06-07 | — | — | CN | claimed |
| CN-109721560-A | A kind of preparation method of irsogladine maleate | 于鹏 | 2019-05-07 | — | — | CN | claimed |
| CN-106187928-A | A kind of preparation method of irsogladine maleate | 安徽省逸欣铭医药科技有限公司 | 2016-12-07 | — | — | CN | claimed |
| CN-106083547-A | The pharmaceutical composition of irsogladine maleate and the application in biological medicine thereof | 刘慎权 | 2016-11-09 | — | — | CN | claimed |
| CN-102579453-B | Compound preparation for treating gastric ulcer and preparation method of same | ZHAOKE PHARMACEUTICAL HEFEI CO LTD | 2014-07-16 | — | — | CN | claimed |
| CN-102579453-A | Compound preparation for treating gastric ulcer and preparation method of same | ZHAOKE PHARMACEUTICAL HEFEI CO LTD | 2012-07-18 | — | — | CN | claimed |
| CN-101940559-A | Orally-taken solid preparation containing gastric mucosa protective agent and application thereof | FEI LIN | 2011-01-12 | — | — | CN | claimed |
| EP-0580860-B2 | METHOD OF MANUFACTURING SOLID DISPERSION | NIPPON SHINYAKU CO LTD (JP) | 2004-12-15 | — | — | EP | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-5700410-A | Method of manufacturing wax matrices | NIPPON SHINYAKU CO., LTD. (JP) | 1997-12-23 | — | — | US | claimed |
| EP-0580860-B1 | METHOD OF MANUFACTURING SOLID DISPERSION | NIPPON SHINYAKU CO LTD (JP) | 1997-10-22 | — | — | EP | claimed |
| US-4487770-A | WITH 2,4-DIAMINO-6-(2',5'-DICHLOROPHENYL)-5-TRIAZINE MALEATE | NIPPON SHINYAKU CO., LTD. (JP) | 1984-12-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12478627-B2 | Irsogladine for the treatment of eosinophilic gastrointestinal diseases | GIPR, EPX, HRH2 | HTR2B 943/4885JAK2 150/4885PDE4D 1307/4885 |
| US-10639308-B2 | sGC stimulators | PTGIS, CGAS, GUCY1A1 | HTR2B 1505/4885JAK2 948/4885PDE4D 190/4885 |
| US-20220226333-A1 | IRSOGLADINE FOR THE TREATMENT OF EOSINOPHILIC GASTROINTESTINAL DISEASES | GIPR, EPX, HRH2 | HTR2B 943/4885JAK2 150/4885PDE4D 1307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.